WATERTOWN, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the Company has dosed its first participant in a Phase 1 clinical trial in healthy volunteers evaluating VG-3927, the first and only small molecule TREM2 agonist in the clinic for the potential treatment of Alzheimer’s disease (AD).

WATERTOWN，Mass。，2023年10月17日（GLOBE NEWSWIRE）-致力于利用小胶质细胞治疗神经退行性疾病的临床阶段生物技术公司Vigil Neuroscience，Inc。（纳斯达克股票代码：VIGL），今天宣布该公司已将其第一位参与评估VG-3927的健康志愿者的1期临床试验，临床上第一种也是唯一一种用于治疗阿尔茨海默病（AD）的小分子TREM2激动剂。

“Dosing the first participant in our Phase 1 trial of VG-3927, the first and only small molecule TREM2 agonist in clinical development for assessment in AD, is an important milestone in our multi-modality strategy to develop novel therapeutics for the treatment of rare and common neurodegenerative diseases,” said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil.

“给我们第一阶段试验的第一个参与者服用VG-3927，这是第一个也是唯一一个在临床开发中用于AD评估的小分子TREM2激动剂，是我们开发治疗罕见和常见神经退行性疾病的新疗法的多模式策略中的一个重要里程碑，”IvanaMagovčević-Liebisch博士说，J.D。，Vigil的总裁兼首席执行官。

“With approximately 6.7 million Americans living with AD, there remains a significant need for new therapies with improved safety and efficacy and that can broadly address multiple aspects of AD disease pathophysiology. Our orally bioavailable and highly CNS penetrant TREM2 agonist VG-3927 has a differentiated mechanism of action with multiple potential therapeutic advantages in AD, and we are excited to advance VG-3927 to potentially bring a differentiated treatment option to AD patients.” The double-blind, placebo-controlled Phase 1 clinical trial plans to evaluate VG-3927 in SAD (single) and MAD (multiple) ascending dose cohorts in healthy volunteers.

“大约有670万美国人患有AD，仍然非常需要具有改善的安全性和功效的新疗法，并且可以广泛地解决AD疾病病理生理学的多个方面。我们的口服生物可利用性和高度CNS渗透性TREM2激动剂VG-3927具有差异化作用机制在AD中具有多种潜在的治疗优势，我们是很高兴推进VG-3927，可能为AD患者带来不同的治疗选择。”双盲，安慰剂对照的1期临床试验计划评估健康志愿者中SAD（单）和MAD（多）递增剂量队列中的VG-3927。

The study is designed to evaluate VG-3927’s safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD). The Company anticipates reporting interim Phase 1 topline data in mid-2024. About VG-3927Vigil’s highly active, selective, and brai.

该研究旨在评估VG-3927的安全性和耐受性，药代动力学（PK）和药效学（PD）。该公司预计在2024年中期报告中期1期临床数据。关于VG-3927Vigil的高活性，选择性和brai。